Pasithea Therapeutics (NASDAQ:KTTA) focuses on developing innovative treatments for psychiatric and neurological disorders. The company is deeply engaged in pursuing cutting-edge research and projects aimed at understanding and potentially curing debilitating conditions such as depression, anxiety, and multiple sclerosis. By leveraging advanced science and technology, Pasithea Therapeutics is on a mission to improve mental health care and offer new hope to patients through novel therapeutic approaches. Their objectives are centered around bringing breakthrough therapies from the lab to the clinic, ultimately aiming to transform the way these diseases are treated worldwide.